HABA Laboratories, Inc. AI Stock Analysis
Want to see JP:4925 full AI Analyst Report?
HABA Laboratories, Inc. (4925) AI Stock Analysis
HABA Laboratories, Inc.
(TSE/TYO:4925)
The company's financial health is a key strength, driven by a robust balance sheet and a return to profitability. However, the stock is under significant technical pressure, trading in a clear downtrend across all major moving averages with weak momentum. A low P/E ratio and decent dividend yield provide some valuation support, but the negative price trend remains the most significant headwind.
HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.25B
- Dividend Yield
- 2.42%
- Average Volume (3M)
- 1,898
- Price to Earnings (P/E)
- 10.8
- Beta (1Y)
- 0.29
- Revenue Growth
- -2.92%
- EPS Growth
- -25.96%
- Country
- Japan
- Employees
- 523
- Sector
- General
- Sector Strength
- 55
- Industry
- Household & Personal Products
HABA Laboratories, Inc. Business Overview & Revenue Model
Company Description
Established in Tokyo, Japan, in 1983, HABA Laboratories, Inc. develops and distributes a comprehensive range of skincare, hair, and body care items both domestically and across international markets. Their skincare portfolio encompasses facial cleans...
How the Company Makes Money
HABA Laboratories, Inc. makes money primarily by selling its branded skincare and beauty products to consumers. Key revenue streams typically include (1) direct product sales through company-operated channels (e.g., retail stores and/or e-commerce),...
HABA Laboratories, Inc. Financial Statement Overview
Summary
The company has returned to profitability with a net margin of 6.3% and maintains a very strong balance sheet (debt/equity 0.12, equity ¥9.54B). Cash flow generation is solid, with free cash flow covering 94% of net income, though revenue growth is modest at 1.3%.
Income Statement
75PositiveBalance Sheet
88Very PositiveCash Flow
70Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.04B | 12.14B | 12.06B | 12.32B | 12.04B | 12.91B |
| Gross Profit | 7.96B | 7.95B | 7.99B | 8.03B | 8.17B | 8.79B |
| EBITDA | 802.02M | 898.40M | 811.56M | -1.31B | 17.05M | 448.30M |
| Net Income | 680.57M | 760.36M | 576.57M | -2.12B | -707.87M | -269.03M |
Balance Sheet | ||||||
| Total Assets | 11.66B | 12.52B | 12.34B | 12.43B | 14.73B | 15.76B |
| Cash, Cash Equivalents and Short-Term Investments | 5.15B | 5.78B | 4.74B | 3.96B | 4.82B | 5.65B |
| Total Debt | 959.17M | 1.19B | 1.82B | 2.36B | 2.03B | 2.56B |
| Total Liabilities | 2.31B | 2.98B | 3.42B | 3.92B | 3.96B | 4.12B |
| Stockholders Equity | 9.35B | 9.54B | 8.93B | 8.51B | 10.77B | 11.64B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.16B | 1.48B | -1.02B | -232.69M | 1.53B |
| Operating Cash Flow | 0 | 1.24B | 1.62B | -587.92M | 55.96M | 1.71B |
| Investing Cash Flow | 0 | 484.54M | -147.18M | -441.79M | -214.40M | -216.49M |
| Financing Cash Flow | 0 | -780.75M | -689.49M | 171.06M | -676.32M | -1.51B |
HABA Laboratories, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Negative. The current price of 1650.00 is below the 20-day moving average (MA) of 1665.75, below the 50-day MA of 1690.78, and below the 200-day MA of 1716.37, indicating a bearish trend. The MACD of -10.26 indicates Positive momentum. The RSI at 34.15 is Neutral, neither overbought nor oversold. The STOCH value of 31.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4925.
HABA Laboratories, Inc. Peers Comparison
Overall Rating
JP:493383Outperform
JP:491869Neutral
JP:492668Neutral
JP:492565.6Neutral
JP:492058Neutral
JP:493644Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 83Outperform | JPY 44.30B | 22.82 | ― | 0.88% | 19.48% | -22.87% | |
| 69Neutral | JPY 2.91B | 15.00 | ― | 2.92% | -5.54% | -55.93% | |
| 68Neutral | JPY 5.33B | 20.94 | ― | 1.61% | 1.51% | -18.54% | |
| 66Neutral | JPY 6.24B | 10.81 | ― | 2.42% | -2.92% | -25.96% | |
| 58Neutral | JPY 2.21B | 8.25 | ― | 2.84% | 9.96% | 2053.18% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 44Neutral | JPY 6.65B | -13.57 | ― | 3.62% | -0.08% | -246.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4925 | HABA Laboratories, Inc. | 1650.00 | 16.13 | 0.99% | |
| JP:4918 | Ivy Cosmetics Corporation | 513.00 | 196.11 | 61.88% | |
| JP:4920 | Nippon Shikizai, Inc. | 1056.00 | 7.47 | 0.71% | |
| JP:4926 | C'BON COSMETICS Co., Ltd. | 1246.00 | 71.30 | 6.07% | |
| JP:4933 | I-ne CO., LTD. | 2501.00 | 1115.22 | 80.48% | |
| JP:4936 | AXXZIA, Inc. | 276.00 | -123.10 | -30.84% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
